Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We read with interest the recently published article by Arnold et al titled “Macular Xanthophylls and ω-3 Long-Chain Polyunsaturated Fatty Acids in Age-Related Macular Degeneration: A Randomized Trial.”1 The authors report the results of a 12-month intervention with macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in patients with nonexudative age-related macular degeneration (AMD), where the main outcome measures included plasma xanthophyll concentrations and optical density of macular pigment (MP). Unfortunately, however, the methods used to assess these outcome measures were flawed, thereby rendering the conclusion of the article unsafe.
Meagher KA, Nolan JM, Beatty S. Regarding Macular Xanthophylls and ω-3 Long-Chain Polyunsaturated Fatty Acids in Age-Related Macular Degeneration. JAMA Ophthalmol. 2014;132(2):230-231. doi:10.1001/jamaophthalmol.2013.6667